ProCE Banner Activity

Phase III IMvigor010: Adjuvant Atezolizumab vs Observation in Patients With High-Risk Muscle-Invasive Urothelial Cancer

Slideset Download
Conference Coverage
Adjuvant atezolizumab did not improve disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma compared with observation.

Released: June 08, 2020

Expiration: June 07, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono